Evaluation of terminal complement cascade inhibitors using in vitro and in vivo models of age-related macular degeneration and in Alzheimer’s Disease

Age-related macular degeneration (AMD) is a leading cause of blindness that is estimated to affect over 6 million people globally. There are currently no approved treatments for dry AMD, the most common form of the disease. Various lines of inquiry suggest that dysregulation of a part of the innate immune system called complement plays a key role in the progression of AMD. This research project aims to (a) further explore the underlying causes of the disease, and (b) evaluate potential treatments in pre-clinical studies. Interns will conduct laboratory experiments using model systems and investigational drugs. Research results will help guide the partner organization’s drug development program.

Faculty Supervisor:

Joanne Matsubara


Gideon Obasanmi


Paragon Ventures




Professional, scientific and technical services


University of British Columbia



Current openings

Find the perfect opportunity to put your academic skills and knowledge into practice!

Find Projects